Boltwood Capital Management Decreases Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)


Share on StockTwits

Boltwood Capital Management lowered its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.2% in the 1st quarter, HoldingsChannel reports. The firm owned 2,975 shares of the biopharmaceutical company’s stock after selling 195 shares during the quarter. Boltwood Capital Management’s holdings in Alexion Pharmaceuticals were worth $455,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. GMT Capital Corp purchased a new position in Alexion Pharmaceuticals in the 4th quarter valued at approximately $10,687,000. 9258 Wealth Management LLC grew its stake in Alexion Pharmaceuticals by 4.1% in the 4th quarter. 9258 Wealth Management LLC now owns 5,650 shares of the biopharmaceutical company’s stock valued at $883,000 after buying an additional 222 shares in the last quarter. Varma Mutual Pension Insurance Co purchased a new position in Alexion Pharmaceuticals in the 4th quarter valued at approximately $2,343,000. Magnetar Financial LLC purchased a new position in Alexion Pharmaceuticals in the 4th quarter valued at approximately $184,465,000. Finally, Dupont Capital Management Corp grew its stake in Alexion Pharmaceuticals by 84.2% in the 4th quarter. Dupont Capital Management Corp now owns 21,685 shares of the biopharmaceutical company’s stock valued at $3,388,000 after buying an additional 9,912 shares in the last quarter. Institutional investors and hedge funds own 87.27% of the company’s stock.

Alexion Pharmaceuticals stock traded up $2.46 during mid-day trading on Thursday, hitting $154.81. The company’s stock had a trading volume of 11,803 shares, compared to its average volume of 2,710,022. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.81 and a quick ratio of 3.26. The stock has a market cap of $34.03 billion, a price-to-earnings ratio of 35.60, a price-to-earnings-growth ratio of 0.75 and a beta of 1.33. The business has a 50 day moving average price of $152.91 and a 200-day moving average price of $140.23. Alexion Pharmaceuticals, Inc. has a 12 month low of $94.23 and a 12 month high of $162.60.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Wednesday, February 3rd. The biopharmaceutical company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.56 by $0.40. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.51 billion. Alexion Pharmaceuticals had a net margin of 16.32% and a return on equity of 23.16%. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.71 earnings per share. On average, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 11.14 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on ALXN shares. Robert W. Baird lowered shares of Alexion Pharmaceuticals from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $140.00 to $175.00 in a research note on Monday, December 14th. Royal Bank of Canada raised their price target on shares of Alexion Pharmaceuticals from $139.00 to $175.00 and gave the company an “outperform” rating in a report on Monday, December 14th. Roth Capital raised their price target on shares of Alexion Pharmaceuticals from $50.00 to $73.00 in a report on Tuesday, December 15th. BMO Capital Markets downgraded shares of Alexion Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their price target for the company from $152.00 to $175.00 in a report on Monday, December 14th. Finally, Piper Sandler downgraded shares of Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Thursday, February 4th. Eighteen research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Alexion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $151.83.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

Recommended Story: What does an outperform rating mean?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.